Ras oncogene mutation in multiple myeloma - Wikidata - awgldk - TriplyDB

Ras oncogene mutation in multiple myeloma

Ras oncogene mutation in multiple myeloma

http://www.wikidata.org/entity/Q36356976

about

An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth.Multiple Myeloma and Chronic Lymphocytic Leukemia: Commonalities and Differences in Biology and Therapy.Serial exome analysis of disease progression in premalignant gammopathies.Chromosomal and genetic abnormalities in myeloma.Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proto-oncogene analysis in multiple myeloma Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.Growth factors and antiapoptotic signaling pathways in multiple myeloma.Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation.Plasma cell myeloma and related neoplasms.MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma.Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.Multiple myeloma: why does the disease escape from plateau phase?N- and K-ras oncogenes in plasma cell dyscrasias.Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2).T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes.The retinoblastoma susceptibility gene RB-1 in multiple myeloma.Multiple myeloma: prognosis and standard treatment.The biological features of multiple myeloma.Multiple myeloma: increasing evidence for a multistep transformation process.Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.Co-expression of B7-1 with Interleukin-12 Enhances Vaccine-induced Antitumour Immunity in Experimental Myeloma.Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases.Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Molecular analysis of the IL-6 receptor in human multiple myeloma, an IL-6-related disease High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles

P2860

Q30885275-59DFA85D-671A-4502-AAB7-E66B2BF63FAD Q33434182-C9DC1F2D-1864-4577-AAC2-6C486777A657 Q34079934-CB72C072-55F2-4C5A-8D49-3C5EB6732C5A Q34929064-136933BF-A73D-490F-909A-37753C3EC1C0 Q35034152-B20B0F85-38EB-42FA-B2F3-4CB5957F8936 Q35186888-ED53A5E0-780A-4CA9-A0FE-F3BEAECAF5C6 Q35734509-EE4735D3-295A-4CD7-A4AD-1F444967B310 Q35832022-BA74E4C7-5823-4B2C-974A-65922173C6BB Q35982162-0BBF2872-2C66-4B19-86FF-541276F1E16F Q36080374-EE22D368-68F6-4AFA-83C2-678F95833EC6 Q36292888-5F302D4E-5062-4B37-B1F1-CD08DAF64C5C Q36414422-15EFDF14-DE09-4B3A-BBC6-E643523BC2D1 Q36430152-84689BBA-C62F-4293-89D3-5C717AC55706 Q37901231-7BDF7D4F-9CC9-4045-A20D-FC490F926ACD Q38092584-974FFF8E-D077-43A1-B1DF-A2C7EC4D33BA Q38192044-FF8A36A2-E9FA-4AB3-836D-775C8247E63D Q38730889-6AA2F571-3882-4394-A45B-8B8DE5DA6457 Q38950582-AE8BFEFB-3FA6-4FBF-ACEF-C78D2DAF59F9 Q39771144-6974D77B-4819-47AC-BD00-58EF7E08037E Q39809474-C3BA1986-D947-41F4-80EB-FB8D63D22779 Q40312071-5EED60FD-8F62-47AD-87E8-B0D1C4B1EB31 Q40567866-89F949A3-8B7D-4DF1-9384-7C97932BB6C5 Q40594604-0256AB15-692E-4F2A-9FA9-7D59EC93235D Q40683311-16ACD183-2CD7-4847-B480-E97CBA8C9E4F Q40706864-C6361778-F6F6-473C-92CC-2294CAF94729 Q40712555-C8B936DA-5216-450C-9846-F31A96806C4B Q40963467-50AC5959-B451-4F4B-812F-2C886AF428FF Q41139639-E2987741-878C-43DD-AB36-9A263864FEA5 Q41348057-D747E740-3625-4D78-B104-CB768C345B86 Q41348077-BAE86F4C-BD8D-435B-8249-D2A76B1926C9 Q41670812-F06564E7-B03D-480E-B255-EB730E7EF877 Q44279405-83444ED7-085E-40E7-A68A-FAC4119DBB1E Q44319734-B60EF31E-5614-429D-B550-A0B7B6F0B736 Q45856286-6AA8822F-FEAF-4210-95B5-2AA5527EEF46 Q48020548-7155B7AD-6B21-498A-B6B4-F519C606E6F2 Q48073647-91C4DA54-78A9-486F-98CC-FF505D3FFF12 Q49021003-E6976D95-C169-42B4-9F7D-D40F6BD67B65 Q57287670-7A54F061-BE8B-4D53-B832-D28B9DFFBE84 Q57785902-78437838-43A6-402C-A915-FDE63369F8F3 Q58321395-F72B4275-B6BC-4954-9C75-8AE356439BF2

P2860

Ras oncogene mutation in multiple myeloma

http://www.wikidata.org/entity/Q36356976

description

1989 nî lūn-bûn

@nan

1989年の論文

@ja

1989年学术文章

@wuu

1989年学术文章

@zh-cn

1989年学术文章

@zh-hans

1989年学术文章

@zh-my

1989年学术文章

@zh-sg

1989年學術文章

@yue

1989年學術文章

@zh

1989年學術文章

@zh-hant

name

Ras oncogene mutation in multiple myeloma

@ast

Ras oncogene mutation in multiple myeloma

@en

type

label

Ras oncogene mutation in multiple myeloma

@ast

Ras oncogene mutation in multiple myeloma

@en

prefLabel

Ras oncogene mutation in multiple myeloma

@ast

Ras oncogene mutation in multiple myeloma

@en

P1433

Q36356976-0FAB1462-0E56-4080-B620-42146CE6D0E9

P1476

Q36356976-EF1DA195-54C1-46DF-85BB-DFE7DC1B3684

P2093

Q36356976-0C4E4F41-4CF5-4866-8257-FAE1E7BD2AF2

Q36356976-0F921B98-BA27-43EF-841D-5686014D4475

Q36356976-0FF56F19-4724-49F3-A3B5-B140F891AA4B

Q36356976-383CCA29-AB82-4608-A824-FC265E7DFEEC

Q36356976-8389D2C3-900B-4B3B-AE5D-E028C89B5D70

Q36356976-E6E4F49F-A5FB-455A-80B6-386B65CE44AE

Q36356976-F2DD88F4-0A11-406D-8906-FAA8156550B5

P2860

Q36356976-05C5263F-024A-4C49-A5A4-A6597BCA7D4F

Q36356976-06358BB0-3153-4086-9AE7-004DBA61ED39

Q36356976-1A1AF867-9B15-4174-A34A-F41DE03EB028

Q36356976-1AF5351F-AB5E-43D6-BF7E-128F8E2BB893

Q36356976-207C6010-D50E-4C89-98B3-6A6ACBBE7AA0

Q36356976-30098099-2097-4622-ACF2-F000746FA1E9

Q36356976-3985F0E3-E78B-434F-A99F-1A84877EABE7

Q36356976-4B6A9F74-4E7B-470F-86B3-CA8D7892EEB2

Q36356976-51048402-4D01-4FA2-81F0-B8C71F002136

Q36356976-521104E4-131A-43AB-A0DA-0AC645EE002B

P304

Q36356976-C0381130-D7EE-406A-98C6-239DD2FB0089

P31

Q36356976-FEF98328-07E1-4128-9EAF-4179D25FF6C4

P356

Q36356976-76D9C108-4B43-44B4-84A7-026CF08EC297

P407

Q36356976-5DA98635-B932-4E71-99B2-59E43CCD8117

P433

Q36356976-647506BD-CCDC-415B-ADE1-48689D408429

P478

Q36356976-806E6D54-923C-40A2-98A2-9D504C1A1CE6

P577

Q36356976-94409765-1A5E-4B2F-A355-FDC355CA2397

P698

Q36356976-D3C308AE-B9C7-496D-8449-9C839D404A49

P932

Q36356976-49B96F0E-FC67-4DD0-9881-90475AF5B82B

P356

P1433

Journal of Experimental Medicine

P1476

Ras oncogene mutation in multiple myeloma

@en

P2093

A Neri

http://www.w3.org/2001/XMLSchema#string

C Tarella

http://www.w3.org/2001/XMLSchema#string

D Ferrero

http://www.w3.org/2001/XMLSchema#string

J P Murphy

http://www.w3.org/2001/XMLSchema#string

L Baldini

http://www.w3.org/2001/XMLSchema#string

L Cro

http://www.w3.org/2001/XMLSchema#string

R Dalla-Favera

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of RAS oncogene mutations in human lymphoid malignancies

Detection of specific sequences among DNA fragments separated by gel electrophoresis

Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase

A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity

Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.

Characterization of c-Ki-ras oncogene alleles by direct sequencing of enzymatically amplified DNA from carcinogen-induced tumors.

P304

1715-1725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.170.5.1715

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P577

1989-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

2681517

http://www.w3.org/2001/XMLSchema#string

P932

2189505

http://www.w3.org/2001/XMLSchema#string